August 26, 2021 – 09:52
Pfizer CEO Albert Bourla said Tuesday that he believes a Covid-19 vaccine-resistant variant is likely to appear one day, but added that Pfizer has a well-established system that can adapt vaccines to the new variant. within three months.
“Every time a new variant appears in the world, our scientists go to study it. They look to see if this type is resistant to our vaccine. “We have not yet identified such a variant, but we believe it will appear,” Bourla told Fox News.
Bourla added that the company could develop a specific vaccine for a particular variant within 95 days of its identification. According to the U.S. Centers for Disease Control and Prevention (CDC), 62.5% of adults in the U.S. were fully vaccinated, and 73.1% received at least one dose.Bourla said Pfizer is also working on a vaccine for children ages 5 to at 11 years old and that research on vaccines for children will be completed in September.
After that, he says, the company plans to work on a vaccine for children under 5. He also said the company gave the Pfizer-BioNTech COVID-19 vaccine a new name: Comirnaty.
Asked why they simply do not call it the “Pfizer vaccine”, Bourla said the thing is in the laws. “There are specific laws on how you can name your product. Comirnaty is a combination of several words. ” “Co ‘is for covid and’ calm ‘is for mRNA, with all the name referring to the community,” he said.
According to the company, more than one billion doses of the vaccine have been used worldwide, making it one of the most studied drugs in the world. ”We have submitted a well-developed proposal by the FDA.
The report we sent to the agency has 360,000 pages of complete data. I do not think there is any other medicine in the world that has been analyzed so much; “not only during clinical trials, but also in terms of real information coming from the field”, concluded Bourke./EO